title: Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia.
abstract: The data we discuss indicate substantial recent progress in understanding and treating CLL. However, despite considerable new information, many of the intriguing issues we posed at previous IWCLL meetings remain unanswered. Prominent among these are the questions of what causes CLL, what is the relation between CLL and normal B-cell development, are T-cell abnormalities a cause of consequence of CLL, why are auto-immune features so prominent and how is CLL best treated? Although these gaps in our knowledge are unfortunate, they give us the opportunity for yet another IWCLL meeting: 1996 in Greece. More to follow.
authors.affiliation: Salick Health Care Inc, Los Angeles, CA.
authors.forename: R P
authors.initials: RP
authors.lastname: Gale
authors.forename: F
authors.initials: F
authors.lastname: Caligaris-Cappio
authors.forename: G
authors.initials: G
authors.lastname: Dighiero
authors.forename: M
authors.initials: M
authors.lastname: Keating
authors.forename: E
authors.initials: E
authors.lastname: Montserrat
authors.forename: K
authors.initials: K
authors.lastname: Rai
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000276:immunology; D016026:Bone Marrow Transplantation; D018956:CD5 Antigens; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009857:Oncogenes; D016192:Resting Phase, Cell Cycle
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D018956:CD5 Antigens